7SS Stock Overview
Engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Brii Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.12 |
| 52 Week High | HK$0.24 |
| 52 Week Low | HK$0.10 |
| Beta | 1.49 |
| 11 Month Change | -2.50% |
| 3 Month Change | 11.43% |
| 1 Year Change | -64.76% |
| 33 Year Change | -97.55% |
| 5 Year Change | n/a |
| Change since IPO | -94.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7SS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.6% | -0.7% | -0.02% |
| 1Y | -64.8% | -17.2% | 8.2% |
Return vs Industry: 7SS underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 7SS underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 7SS volatility | |
|---|---|
| 7SS Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7SS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7SS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 95 | Zhi Hong | www.briibio.com |
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.
Brii Biosciences Limited Fundamentals Summary
| 7SS fundamental statistics | |
|---|---|
| Market cap | €90.20m |
| Earnings (TTM) | -€35.18m |
| Revenue (TTM) | €5.09m |
17.7x
P/S Ratio-2.6x
P/E RatioIs 7SS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7SS income statement (TTM) | |
|---|---|
| Revenue | CN¥38.38m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥38.38m |
| Other Expenses | CN¥303.83m |
| Earnings | -CN¥265.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 100.00% |
| Net Profit Margin | -691.63% |
| Debt/Equity Ratio | 0% |
How did 7SS perform over the long term?
See historical performance and comparison